Data have confirmed that the administration of pioglitazone in patients with T2DM and NAFLD increases the plasma adiponectin concentration [86], leading to a decrease in IHTG and improvement in glycemic control [87]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.